“We’re targeting a company-wide breakeven by 2028,” said Mike Bell, CFO of lab test innovator Guardant Health. Addressing the 2024 Jefferies London Healthcare conference, he said: “The positivity we’ve had on the Average Sales Price (ASP) in the core business could potentially bring that 2028 target forward by maybe one year.”
“ASPs on Guardant 360 have been a real tailwind over the last 12 months or so,” said Bell. This has primarily been driven by the Medicare pricing increase from $3,500 to $5,000 for the Guardant 360 genomic cancer test
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?